Imfinzi (durvalumab)

Pharma

AZ's perioperative Imfinzi extends life in bladder cancer type

Imfinzi's survival win in muscle-invasive bladder cancer came from a perioperative regimen, a design that's been criticized by the FDA in lung cancer.

Angus Liu Sep 15, 2024 10:30am

Amid concerns, FDA approves AZ's Imfinizi in perioperative NSCLC

Aug 16, 2024 10:51am

FDA's ODAC calls for revamp of perioperative NSCLC trials

Jul 25, 2024 5:00pm

Enhertu stalls as AZ, Daiichi navigate 'harder yards' for ADC

Jul 25, 2024 11:12am

AZ set to face tough questions on Imfinzi expansion bid in NSCLC

Jul 24, 2024 8:29am

AstraZeneca's Imfinzi counts a trial win and a miss

Jun 25, 2024 11:00am